Emergent Biosolutions secures $64.5 million ASPR contract boost for botulism antitoxin

Emergent Biosolutions secures $64.5 million ASPR contract boost for botulism antitoxin
Emergent wins $64.5M ASPR contract

Emergent Biosolutions announced it has received a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR) to support its botulism antitoxin supply.

The contract modification marks a significant boost in Emergent Biosolutions collaboration with the U.S. government for national health security and pharmaceutical preparedness.

Emergent Biosolutions is scheduled to review its first quarter 2026 financial results in an upcoming investor call. The company has recently expanded its role in government response efforts, partnering with multiple countries to strengthen pandemic and bioterrorism defenses as reported in its global health crisis collaboration. These initiatives reflect ongoing activity in national and international health preparedness.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.